A Large Pooled Safety Analysis of 3 Post-Marketing Studies Conducted in Inflammatory Bowel Disease Patients Treated with Biosimilar Infliximab (CT-P13)

(1) Celltrion,Incheon,Korea (Republic of)

(2) Celltrion Healthcare,Incheon,Korea (Republic of)



This item was part of the IBD I (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019